Abstract | BACKGROUND: Non-invasive liquid biopsies of circulating tumor DNA (ctDNA) is a rapidly growing field in the research of non-small cell lung cancer (NSCLC). In this study, factors affecting the concordance of mutations in paired plasma and tissue and the detection rate of ctDNA in real-world Chinese patients with NSCLC were identified. METHODS: Peripheral blood and paired formalin-fixed paraffin-embedded tumor tissue samples from 125 NSCLC patients were collected and analyzed by sequencing 15 genes. Serological biomarkers were tested by immunoassay. RESULTS: The overall concordance between tumor and plasma samples and the detection rate of somatic mutations in ctDNA was 69.2% and 78.4%, respectively. The concordance and detection rate raised with clinical stage were stage I: 14.3%, 14.3%; stage II: 53.3%, 60.0%; stage III: 71.4%, 78.1%; stage IV: 74.1%, 85.2%. With increased tumor diameter, the concordance and detection rate raised from 33.33% to 71.64% and 33.33% to 80.8%, respectively. For patients with partial response, stable disease, progressive disease, and who were treatment-naïve, the concordance and detection rates were 0.0%, 62.7%, 75.2, 73.6%, and 16.7%, 61.9%, 83.3%, 86.5%, respectively. Serological markers: CEA, CA125, NSE, and CYFRA21-1 were significantly higher for patients with detectable somatic alterations in ctDNA than in those who were ctDNA negative (17.08 ng/mL vs. 3.95 ng/mL, 21.63 U/mL vs. 18.27 U/mL, 17.68 U/mL vs. 14.14 U/mL, and 6.55 U/mL vs. 3.81 U/mL, respectively). CONCLUSION: Advanced-stage, treatment naïve or poor therapy outcome, and large tumor size were associated with a high concordance and detection rate. Patients with detectable mutations in ctDNA had a higher level of carcinoembryonic antigen, CA125, NSE, and CYFRA21-1.
|
Authors | Meng Zhang, Yi Feng, Changda Qu, Meizhu Meng, Wenmei Li, Meiying Ye, Sisi Li, Shaolei Li, Yuanyuan Ma, Nan Wu, Shuqin Jia |
Journal | The International journal of biological markers
(Int J Biol Markers)
Vol. 37
Issue 4
Pg. 386-394
(Dec 2022)
ISSN: 1724-6008 [Electronic] United States |
PMID | 35791673
(Publication Type: Journal Article)
|
Chemical References |
- Circulating Tumor DNA
- antigen CYFRA21.1
- CA-125 Antigen
- DNA
- Biomarkers, Tumor
|
Topics |
- Humans
- Carcinoma, Non-Small-Cell Lung
(pathology)
- Circulating Tumor DNA
(genetics)
- Lung Neoplasms
(pathology)
- High-Throughput Nucleotide Sequencing
- Mutation
- CA-125 Antigen
- DNA
- China
- Biomarkers, Tumor
(genetics)
|